SEC Form 4 · accession 0000899243-18-029386
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jayson Donald Alexander Dallas
Officer — President and CEO · Director
Period of report
Nov 19, 2018
Accepted (ET)
Nov 19, 2018 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Nov 19, 2018 | P | 3,600 | $27.558 | A | 63,600 | D | |
| Common Stock, $0.0001 par value | Nov 19, 2018 | P | 50 | $27.5599 | A | 63,650 | D |
Table II — derivative securities
No Table II lines on this filing.